Taking GLP-1 drugs before hospitalization does not worsen ICU outcomes despite muscle loss concerns
In a propensity-matched analysis of 15,191 ICU patients, prior GLP-1 agonist use was not associated with worse in-hospital mortality, hospital length of stay, or ICU length of stay compared to matched controls.
Quick Facts
What This Study Found
Prior GLP-1 agonist use showed no association with adverse ICU outcomes: in-hospital mortality 5.1% vs 4.9% (OR 1.05, 95% CI 0.58-1.91), hospital LOS 13.7 vs 13.4 days, ICU LOS 5.9 vs 5.4 days. All differences were non-significant.
Key Numbers
15,191 eligible ICU patients. 468 (3.1%) had GLP-1 prescriptions within 12 months before admission. 452 propensity-matched pairs analyzed. Similar in-hospital mortality, hospital LOS, and ICU LOS between groups.
How They Did This
Retrospective propensity-matched cohort study using Stanford Health Care data (Jan 2015-Jul 2024). 15,191 eligible ICU patients, 468 with prior GLP-1 use, 452 matched pairs created using high-dimensional propensity score matching with lasso regression.
Why This Research Matters
As millions take GLP-1 drugs and concerns grow about muscle loss side effects, this is the first study examining whether GLP-1 users fare worse during critical illness. The reassuring null finding suggests clinicians need not be concerned about GLP-1-related risks in ICU settings.
The Bigger Picture
This addresses a critical safety question: as GLP-1 prescriptions surge, patients on these drugs will inevitably face hospitalization and critical illness. Finding no adverse ICU outcomes helps allay fears that GLP-1-related body composition changes compromise resilience during severe illness.
What This Study Doesn't Tell Us
Retrospective observational design cannot establish causation. Single-center (Stanford) may limit generalizability. Could not assess GLP-1 dose, duration, or adherence. 3.1% exposure rate may limit power for rare outcomes. No data on functional recovery or ICU-acquired weakness specifically.
Questions This Raises
- ?Would longer-duration GLP-1 use (>12 months) with greater lean mass loss show different ICU outcomes?
- ?Does prior GLP-1 use affect ICU-acquired weakness and functional recovery specifically?
- ?Should GLP-1 drugs be continued, held, or discontinued during critical illness?
Trust & Context
- Key Stat:
- No difference in ICU outcomes Prior GLP-1 agonist use showed mortality OR 1.05 (p=0.88) with no significant differences in hospital or ICU length of stay
- Evidence Grade:
- Large retrospective propensity-matched cohort study with rigorous statistical methodology (high-dimensional propensity scoring, lasso regression). Strong for observational evidence but limited by single-center design.
- Study Age:
- Published in 2025; the first study to examine GLP-1 agonist use and critical care outcomes.
- Original Title:
- Prior GLP-1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity-matched analysis.
- Published In:
- Journal of hospital medicine (2025)
- Authors:
- Park, Albert K, Hom, Jason(3), Lorenzo, Javier, Rao, Vidya, Hui, Gavin, Vickers, Matthew, Ahuja, Neera
- Database ID:
- RPEP-12956
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Is it safe to be on GLP-1 drugs if you end up in the ICU?
This study found no evidence that taking GLP-1 drugs before hospitalization worsened ICU outcomes. Mortality, hospital stay, and ICU stay were all similar between GLP-1 users and matched non-users. While more research is needed, this is reassuring for patients on these medications.
Why were there concerns about GLP-1 drugs and critical illness?
GLP-1 drugs cause weight loss that includes some lean muscle mass. Since ICU patients already experience severe muscle breakdown (protein catabolism) and often develop ICU-acquired weakness, there were concerns that GLP-1-related muscle loss could make critical illness outcomes worse. This study found no such association.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12956APA
Park, Albert K; Hom, Jason; Lorenzo, Javier; Rao, Vidya; Hui, Gavin; Vickers, Matthew; Ahuja, Neera. (2025). Prior GLP-1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity-matched analysis.. Journal of hospital medicine. https://doi.org/10.1002/jhm.70228
MLA
Park, Albert K, et al. "Prior GLP-1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity-matched analysis.." Journal of hospital medicine, 2025. https://doi.org/10.1002/jhm.70228
RethinkPeptides
RethinkPeptides Research Database. "Prior GLP-1 agonist use is not associated with adverse inpat..." RPEP-12956. Retrieved from https://rethinkpeptides.com/research/park-2025-prior-glp1-agonist-use
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.